Clinical Trial Update: Lactulose and Glucose Breath Tests as Predictors of Clinical Benefit From Rifaximin in Irritable Bowel Syndrome

View source ↗

Summary

A clinical trial update evaluating whether lactulose and glucose breath tests can predict which Irritable Bowel Syndrome patients will benefit from rifaximin.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Irritable Bowel Syndrome

Drugs mentioned

• XIFAXAN (rifaximin)

Snippet

Sponsor: Pontificia Universidad Catolica de Chile | Conditions: Irritable Bowel Syndrome | Status: UNKNOWN